Hosted on MSN7mon
GSK Announces FDA Acceptance of New Meningococcal Jab BLA
The MenABCWY vaccine candidate combines the antigenic components of GSK’s two popular licensed meningococcal vaccines, Bexsero (MenB) and Menveo (MenACWY). The MenABCWY combination targets the ...
pharmaphorum3d
GSK trails after Pfizer in 5-in-1 meningococcal vaccine race
The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...
pharmaphorum4d
GSK has most to prove after $16 bn Novartis deal
The biggest vaccine brand it has acquired in the deal is Bexsero, a new vaccine to prevent meningitis B, with a further candidate vaccine in late-stage development, MenABCWY. GSK intends to report ...
Zacks.com on MSN15d
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales
GSK plc GSK reported third-quarter 2024 core earnings of $1.27 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.16. Core earnings declined 1% year over year on a ...